Skip to main content
MainBoardListed
Supriya Lifescience Limited Logo

Supriya Lifescience Limited IPO

Supriya Lifescience Limited IPO

IPO Date :
Issue Price :
Allotment Date :
Listing Date :
List Price :
Lot Size:
Subscription:
Listed Price: ₹ 421.00 (+53.65%)

The Initial Public Offering of Supriya Lifescience Limited's culminated in its successful listing on 28-12-2021 at the NSE, BSE trading platform. The company secured 2,55,47,445 Shares through this capital market exercise, with 72,99,270 Shares allocated to new capital formation and ₹500.00 Cr to existing shareholder liquidity.

Investors participated within the price parameters of ₹265 to ₹274, with minimum investment requirements of 54 shares. The subscription period from 16-12-2021 to 20-12-2021 witnessed active investor engagement across categories.

Following the subscription closure, share allotment was processed on 23-12-2021. The subsequent listing established a public market for the company's shares, enabling price discovery and secondary market trading for investors.

Supriya Lifescience IPO Details
Lot(s) Distribution

Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.

IPO Reservation
Supriya Lifescience IPO Key Performance Indicator
Company Financials ( in Lakhs )

Supriya Lifescience IPO About Company

Supriya Lifescience is a manufacturer of Active Pharmaceutical Ingredients (APIs), producing 38 APIs across therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatics, and anti-allergics. Between FY 2017 and FY 2021, it was the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, and one of the largest exporters of Salbutamol Sulphate in FY 2021. The company exports to 86 countries, serving 1,296 customers, including 346 distributors, across Europe, Latin America, Asia, and North America. Its modern manufacturing facility in Maharashtra spans 23,806 sq. m with a reactor capacity of 547 KL/day and seven clean rooms. Supriya Lifescience has acquired an additional 12,551 sq. m plot for expansion and holds regulatory approvals from USFDA, EDQM, TGA-Australia, KFDA-Korea, PMDA-Japan, NMPA-China, and Health Canada for its API exports.


Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."


Supriya Lifescience IPO Strength Factors

NA


Supriya Lifescience IPO Risk Factors

NA


Supriya Lifescience IPO Lead Manager(s)

  • ICICI Securities Limited
  • Axis Capital Limited

Supriya Lifescience IPO Promoter(s)

  1. Satish Waman Wagh

Supriya Lifescience IPO Company Details

Supriya Lifescience Limited
Phone:
address:

Supriya Lifescience IPO Registrar

Link Intime India Private Limited
Name:
Phone:

Supriya Lifescience IPO FAQs